Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?

Front Immunol. 2021 May 19:12:641427. doi: 10.3389/fimmu.2021.641427. eCollection 2021.

Abstract

Endothelial cell (EC) dysfunction causes a number of early and life-threatening post hematopoietic stem cell transplant (HCT) complications that result in a rapid clinical decline. The main early complications are graft-vs.-host disease (GVHD), transplant associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome (SOS). Post-HCT endothelial dysfunction occurs as a result of chemotherapy, infections, and allogeneic reactivity. Despite major advances in transplant immunology and improvements in supportive care medicine, these complications represent a major obstacle for successful HCT. In recent years, different biomarkers have been investigated for early detection of post-transplant endothelial cell dysfunction, but few have been validated. In this review we will define GVHD, TA-TMA and SOS, summarize the current data available in HCT biomarker research and identify promising biomarkers for detection and diagnosis of early HCT complications.

Keywords: GvHD; HCT; SOS; TA-TMA; biomarkers; endothelial dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allografts
  • Animals
  • Biomarkers / blood*
  • Graft vs Host Disease / blood*
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation*
  • Hepatic Veno-Occlusive Disease / blood*
  • Hepatic Veno-Occlusive Disease / etiology
  • Humans
  • Thrombotic Microangiopathies / blood*
  • Thrombotic Microangiopathies / etiology

Substances

  • Biomarkers